By immobilizing allogeneic, bone marrow-derived MSCs in an extracorporeal device, SBI-101 mimics the natural environment of MSCs and enables sustained, dynamic delivery of anti-inflammatory and regenerative secreted factors directly into the patient’s bloodstream.
Realizing the Therapeutic Promise of MSCs
Due to their broad acting, responsive and dynamic immunomodulatory properties, bone-marrow derived MSCs have shown significant therapeutic potential in numerous preclinical models of disease including acute kidney injury, myocardial infarction, type I diabetes mellitus, and graft-versus-host disease, among many others, which together share a common feature of underlying systemic inflammation.